chemotherapy

January 5, 2021January 5, 2021

Trial Confirms Rubraca’s Clinical Benefit Over Chemotherapy

News

Rubraca (rucaparib) is superior to chemotherapy at prolonging life without disease worsening in people with advanced ovarian cancer who received at least two prior lines of chemotherapy, according to top-line data ... Read more

June 23, 2020June 23, 2020

Protein Biomarkers to Gauge Cancer Response to Chemo Identified

News

Investigators using targeted proteomics — a technique to detect proteins of interest — on samples of ovarian cancer found a wide variety of biomarkers that might help predict which chemotherapies patients are more ... Read more

May 27, 2020May 27, 2020

Phase 2 Trial to Test Exercise as Way to Improve Quality of Life in Recurring Ovarian Cancer

News

A new Phase 2 clinical trial in Australia will assess whether exercise can improve the quality of life and physical function of women with recurring ovarian cancer who are on chemotherapy. ... Read more

October 4, 2019October 4, 2019

Adding Veliparib Extends Time Without Disease Progression in Metastatic Ovarian Cancer, Phase 3 Trial Finds

News

Using veliparib in combination with chemotherapy as first-line and then maintenance therapy post-surgery significantly extended the time without disease progression in women with newly diagnosed metastatic high-grade serous (HGS) ovarian ... Read more

July 31, 2019August 26, 2019

NHS England to Cover Lynparza Earlier in Advanced OC Treatment

News

Maintenance treatment with Lynparza (olaparib) is now recommended after response to the first round of platinum-based chemotherapy in women with advanced ovarian cancer on England’s National Health Service (NHS). The decision by ... Read more

July 22, 2019August 26, 2019

Zejula Maintenance Therapy Extends Progression-free Survival in Advanced Ovarian Cancer Patients, Phase 3 Trial Shows

News

Maintenance treatment with Zejula (niraparib) extended the time without disease worsening in women with advanced ovarian cancer who had responded to first-line chemotherapy, according to updated results of a Phase ... Read more

June 28, 2019June 28, 2019

PARP Inhibitors Used in ‘One-two Punch’ Strategy to Kill OC Cells in Mouse Models, Study Shows

News

Researchers have developed a two-step approach that harnesses the aging process of cells, allowing breast and ovarian cancers to be effectively targeted and destroyed in cell and mouse preclinical models. ... Read more

November 5, 2018

Adding GEN-1 to Standard Chemotherapy Halts Advanced Ovarian Cancer Progression, Phase 1b Trial Shows

News

A combination of Celsion’s DNA-based immunotherapy GEN-1 and standard chemotherapy halted disease progression in women with stage III/IV ovarian cancer eligible for surgery, according to results of a Phase 1b trial. The ... Read more

February 2, 2018

‘Warm’ Chemo Given Ovarian Cancer Patients Seen to Delay Recurrence in Phase 3 Trial

News

Results from a recent phase 3 clinical trial show that a specialized type of chemotherapy delivery may delay disease recurrence in newly diagnosed, advanced ovarian cancer patients. The specialized technique, called ... Read more

January 31, 2018January 31, 2018

Compounds Found to Reverse Chemotherapy Resistance in Ovarian Cancer in Lab Tests

News

A research team at Southern Methodist University (SMU) in Dallas, Texas, has identified three compounds that were able to reverse resistance to chemotherapy in ovarian tumors. In lab experiments based on ... Read more